MB-101 (IL-13Rα2) + MB-108 oncolytic virus

N/A

Report date: 2024/11/14 16:49:47

Base Information

Drug NameMB-101 (IL-13Rα2) + MB-108 oncolytic virus
Drug Alias NameMB101+ MB108MB-109
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapyBiologics > Oncolytic virus
Mechanisms of ActionInterleukin-13 receptor subunit alpha-2 modulators
TargetsInterleukin-13 receptor subunit alpha-2
Therapy Area/IndicationsGlioblastomaAstrocytoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaN/A
Originator CompaniesCity Of Hope National Medical CenterMustang Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesMustang Bio Inc
Inactive CompaniesN/A
Active IndicationsGlioblastomaAstrocytoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A